Clinical trial readout dates for Kodiak Sciences Inc, compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is February 2027.
The registry reports these trials have finished collecting primary data. Results often follow within months, and the company may already have reported.
| Phase 3 Tarcocimab tedromer Wet Age-related Macular Degeneration · NCT06556368 | September 2026 Primary data collected |
| Phase 3 KSI-101 Macular Edema Secondary to Inflammation · NCT06996080 | February 2027 Recruiting |
| Phase 3 KSI-101 Macular Edema Secondary to Inflammation · NCT06990399 | April 2027 Recruiting |
| Phase 3 Tabirafusp tedromer Diabetic Macular Edema (DME) · NCT07734844 | August 2028 Recruiting |
Kodiak Sciences Inc reported $89M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-12). Its net loss for that quarter was $66M; at that rate the cash would last about 1 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.
| 8-K Results of Operations — earnings, may carry pipeline updates | 2026-11-12 |